Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
April 30, 2015 6:51 AM EDT
Cantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) price target of $271.00 (from $222.00) amid "strong" Q1 results.
Koffler commented, "Valeant reported revenues of $2.19B (+16% Y/Y) and adjusted non-GAAP EPS of $2.36 in 1Q:15 vs. guidance of 10-15% organic revenue growth and >$2.30 and FactSet consensus of... More
April 29, 2015 10:16 AM EDT
Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 (from $210.00) following Q1 beat and better-than-expected 2016 outlook.
Chen commented, "The 1Q15 beat and better-than-expected outlook for '16+ support our positive thesis for... More
